Octreotide oral - Chiasma

Drug Profile

Octreotide oral - Chiasma

Alternative Names: Chiasma Investigational Product 1; CHIP-1; Mycapssa; Octreolin; Octreotide acetate - Chiasma; Oral Octreotide; RG3806

Latest Information Update: 20 May 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Chiasma
  • Class Antineoplastics; Antisecretories; Cyclic peptides; Indoles; Somatostatins
  • Mechanism of Action Growth hormone releasing factor antagonists; Somatostatin receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Acromegaly
  • New Molecular Entity No

Highest Development Phases

  • Preregistration Acromegaly
  • Discontinued Portal hypertension

Most Recent Events

  • 23 Aug 2017 Chiasma plans the OPTIMAL phase III trial for Acromegaly in USA, Canada, Denmark, Germany, Hungary, Israel, Italy, Netherlands, Poland, Romania, Sweden, Turkey and United Kingdom (NCT03252353)
  • 01 Feb 2016 Chiasma initiates a phase III trial for Acromegaly in USA (NCT02685709)
  • 08 Jan 2016 Chiasma completes a phase III trial in Acromegaly in Germany, Hungary, Slovenia and Poland (PO) (EudraCT2015-001292-51)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top